Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Atenolol

Preparation Calculator

Atenolol

Cardioselective Ξ²1 blocker

AdultBBHTN

Indication

HTN β€’ AF rate β€’ Angina β€’ Post-MI (when used regionally)

At a glance

INDICATIONS (CORE USE)

**HTN**; **AF rate control**; angina. **Renally cleared** β€” **dose adjust CKD**. **Not** a first-line **HFrEF GDMT** choice vs **carvedilol / met succinate / bisoprolol**.

ADULT DOSE (STANDARD)

**PO:** **25–50 mg daily** start β†’ titrate to **HR/BP**; **↓ dose** if **CrCl reduced** per label

MAX DOSE

Label max often **100 mg daily** β€” titrate to effect; **CKD** may cap lower

Route

PO

PEDIATRIC DOSE

Specialist contexts only

Do not miss

Must-not-miss safety points

Major warning

- Bradycardia / AV block - Renal failure β†’ accumulation β€” adjust interval/dose - Abrupt withdrawal

Indications

USE IF: HTN, rate control, angina when Ξ²1 agent desired and renal function allows dosing. AVOID IF: symptomatic bradycardia, high-grade AV block (without pacing), or **dialysis** without dose rule β€” verify label.

Primary

  • Hypertension

Secondary

  • Atrial fibrillation β€” **rate control**
  • Angina / chronic CAD
  • Post–MI (regional practice β€” verify guideline)

Dosing

STANDARD (ADULT PO)

**Once or twice daily** depending on CrCl and region

ADULT DOSE

Start **25–50 mg** daily β†’ titrate to **HR/BP**. **CrCl <35:** extend interval or **↓ dose** per label β€” pharmacy.

PEDIATRIC DOSE

N/A

MAX DOSE

**~100 mg/day** typical ceiling for HTN β€” **CKD** lowers effective max

Practical Note

**Renal** dosing matters more than lipophilic Ξ²-blockers.

Warnings

Clinical warnings

  • Beta1-selective β€” caution in asthma / bronchospasm; not asthma-proof at higher doses. HOLD if HR <50–55, SBP <90–100, symptomatic bradycardia, high-grade AV block, or acute decompensated HF with shock/hypoperfusion.
  • Renal dosing
  • masked hypoglycemia

Adverse effects

  • Bradycardia
  • fatigue
  • cold extremities
  • bronchospasm (rare vs non-selective)

Contraindications

  • Cardiogenic shock
  • Symptomatic bradycardia
  • High-grade AV block (without pacing)
  • Hypersensitivity

Drug interactions

  • Verapamil / diltiazem: avoid or use extreme caution (bradycardia / AV block / hypotension / shock risk)
  • Digoxin: additive AV-node suppression / AV block risk
  • Insulin / sulfonylureas: masks hypoglycemia warning
  • NSAIDs may blunt BP effect

Special populations

Pediatrics

Specialist contexts only

Pregnancy

**Pregnancy:** **labetalol** often preferred for HTN β€” OB guidance. **

Lactation

** present in milk β€” usually low risk at low dose β€” OB.

Renal impairment

**Primary renal elimination** β€” **mandatory** dose/interval adjustment in **CKD** and **dialysis** per label.

Hepatic impairment

Minimal hepatic metabolism β€” less hepatic adjustment than many lipophilic beta-blockers.

Elderly

Start low β€” **renal function** often reduced.

Administration

PO β€” consistent timing.

Monitoring

  • Monitor: - Symptoms β†’ dizziness, syncope, fatigue - **CrCl** when dosing changes or AKI
  • Recheck: - Reassess ECG / PR interval / AV block risk with symptoms, IV use, or dose escalation - Reassess dose / volume / cause within 48–72h after change - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - Hold if:
    - HR <50–55
    - SBP <90–100
    - Symptomatic bradycardia
    - Acute decompensated HF
    - Hypoperfusion / cardiogenic shock
    - Pulmonary edema requiring IV therapy

    Also hold:
    - High-grade AV block
    - Severe orthostasis

Overdose / toxicity

Clinical Picture

A) Mild β†’ bradycardia, hypotension, fatigue B) Moderate β†’ sustained bradycardia + hypotension Β± AV block C) Severe β†’ shock, high-grade AV block, seizures / coma (severe toxicity)

Immediate Actions

β€’ Airway + continuous monitoring first (ABCs, telemetry, BP) β€’ Bradycardia β†’ atropine β€’ Hypotension β†’ IV fluids β€’ Early β†’ IV calcium (CaCl2 / Ca-gluconate) β€’ Glucagon 3–5 mg IV β€’ Repeat or escalate glucagon β†’ infusion if responsive (often transient) β€’ Persistent shock β†’ HIET (insulin + dextrose) β€’ Monitor glucose + potassium closely β€’ Add vasopressors if shock persists β€’ Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) β€’ Refractory severe lipophilic toxicity β†’ IV lipid emulsion (toxicology-guided) β€’ Pacing β†’ symptomatic high-grade AV block β€’ ECMO β†’ refractory shock (per center) β€’ Severe / unstable β†’ ACLS + ICU / toxicology

Antidote

- Glucagon β†’ non-Ξ² pathway (often transient) - IV calcium β†’ inotropy / conduction support - HIET β†’ metabolic rescue (refractory shock) - IV lipid β†’ lipophilic toxicity (refractory / seizures)

Decontamination

β€’ Recent **oral** ingestion β†’ **activated charcoal** if **protected airway** and within **~1–2 h** (ingestion history + risk/benefit)

Escalation

- Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) - Pacing β†’ symptomatic high-grade AV block - ECMO β†’ refractory shock (per center)

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Check CrCl** before **doubling dose**.

Clinical pearls

Renal clearance drives dosing decisions β€” avoid copy/paste HF titration rules from other beta-blockers. *Ξ²-blockers (class):* **Start low, go slow.** **HF:** only **evidence-based agents** (**metoprolol succinate**, **bisoprolol**, **carvedilol**) for **HFrEF GDMT** β€” not all Ξ²-blockers interchangeable. **Rate control (AF)** vs **BP lowering** β€” titrate to the clinical target.

Beta-blocker safety

  • Renal function on initiation
  • Avoid abrupt stop

Pharmacy Tool

Preparation Calculator

Atenolol 2 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

**Renal excretion** β€” half-life prolonged in **CKD**.

Mechanism of action

**Ξ²1** blockade; hydrophilic β€” less CNS penetration than lipophilic beta-blockers.

Common brand names

Saudi Arabia

Tenormin, Atenol

Global

(placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **aortic syndromes** and **thyrotoxic storm** are **protocol-driven** β€” Ξ²-blocker choice and targets are **team + guideline** specific.
  • Ξ²-blocker **GDMT for HFrEF** applies only to **evidence-based agents** β€” verify label and cardiology plan before substituting.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)

Do not miss

  • Teach **not to stop abruptly** after chronic use β€” taper when feasible
  • Titrate to **HR vs BP endpoint** (AF rate control often needs higher exposure than BP alone)
  • Renal function on initiation
  • Avoid abrupt stop